Thyroid cancer

For Cancer Patients, the Pandemic is Not Over

Retrieved on: 
Monday, July 25, 2022

OTTAWA, ON, July 25, 2022 /CNW/ - A recent Canadian Cancer Survivor Network (CCSN) survey shows Canadian cancer patients and caregivers remain fearful and stressed by the COVID-19 pandemic.

Key Points: 
  • OTTAWA, ON, July 25, 2022 /CNW/ - A recent Canadian Cancer Survivor Network (CCSN) survey shows Canadian cancer patients and caregivers remain fearful and stressed by the COVID-19 pandemic.
  • Cancer patients and caregivers are well-aware of the strain the pandemic has placed on the healthcare system and its effects on their access to care.
  • This fourth study focused on cancer patients' and caregivers' levels of anxiety and concerns about receiving adequate cancer care now that COVID-19 restrictions are being lifted.
  • The respondents comprised 1100 people with a cancer diagnosis and 253 caregivers for cancer patients.

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

Retrieved on: 
Wednesday, July 20, 2022

Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the companys RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid nodule fine needle aspiration (FNA) biopsy samples.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the companys RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid nodule fine needle aspiration (FNA) biopsy samples.
  • The Afirma MTC Classifier is included as part of the Afirma testing offering on all orders for patients with thyroid nodules that are deemed indeterminate or suspicious for cancer based on cytopathology evaluation.
  • Our findings show that the Afirma MTC Classifier identifies MTC on pre-operative samples with high accuracy, which may optimize patient outcomes.
  • Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. is available as part of Veracytes CLIA-validated laboratory developed test (LDT) service.

Insilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical Development

Retrieved on: 
Tuesday, July 19, 2022

New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.

Key Points: 
  • New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.
  • The unique opportunity at Insilico allows me to join a world class AI drug discovery team that can rapidly bring novel drugs to patients with a great unmet need, said Sujata Rao M.D., Senior Vice President, Head of Clinical Development at Insilico Medicine.
  • This is a transformative approach to drug development with shortened timelines that I hope will make a huge clinical impact.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Thyroid Cancer Drugs Global Market Research Report 2022: Focus on Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022

The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.
  • The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer.
  • Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market.
  • Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market.

United States Thyroid Cancer Drugs Market Research Report 2022: Cabozantinib-S-Malate, Caprelsa, Cometriq, Doxorubicin Hydrochloride, Ipilimumab, Lenvatinib Mesylate, Nivolumab, and Vandetanib - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022

The "Thyroid Cancer Drugs Market Research Report by Drug Type (Cabozantinib-S-Malate, Caprelsa, and Cometriq), End User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer Drugs Market Research Report by Drug Type (Cabozantinib-S-Malate, Caprelsa, and Cometriq), End User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

Global Liquid Biopsy Market Analysis & Forecasts, 2021-2022 & 2032 - Focus on Offering, Usage, Workflow, Circulating Biomarker, Sample, Technology, Clinical Application, End User - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022

The North America region is expected to dominate the global liquid biopsy market during the forecast period 2022-2032.

Key Points: 
  • The North America region is expected to dominate the global liquid biopsy market during the forecast period 2022-2032.
  • Increasing investments in R&D of liquid biopsy products and services and various research fundings is one of the major opportunities in the global liquid biopsy market.
  • The current global liquid biopsy market comprises various indications such as lung cancer, breast cancer, prostate cancer, and many others.
  • End User (Academic and Research Institutions, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, Other End Users)
    The academic and research institutions segment dominates the global liquid biopsy market.

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

Retrieved on: 
Monday, June 20, 2022

The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.

Key Points: 
  • The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.
  • An example of a forward-looking statement includes, among others, that the Afirma GSC can improve thyroid cancer diagnosis in patients with indeterminate thyroid nodules.
  • The Afirma GSC is available as part of Veracytes CLIA-validated laboratory developed test (LDT) service.
  • Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Global Surgical Clamps Market Report to 2030 - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, June 10, 2022

The "Surgical Clamps Market by Type, Usage, Material and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Clamps Market by Type, Usage, Material and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • Rise in demand for surgical clamps during surgical procedures act a key driving force for expansion of the global market.
  • Thus, rise in use of surgical clamps during cardiac surgeries expected to contribute towards the growth of surgical clamps market.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global surgical clamps market to identify the prevailing opportunities.

OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate

Retrieved on: 
Wednesday, June 8, 2022

Multitude will receive an upfront payment as well as development, regulatory and sales milestone payments, and tiered royalties.

Key Points: 
  • Multitude will receive an upfront payment as well as development, regulatory and sales milestone payments, and tiered royalties.
  • The linker is specially designed to accommodate the exatecan payload, generating a highly stable and homogenous ADC.
  • OnCusp and Multitude have engaged WuXi XDC, a global CRDMO company dedicated to end-to-end bioconjugates services, as the CMC partner for CUSP06.
  • OnCusp Therapeutics is a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics.

World Hypoparathyroidism Day - New Study Shows Surgeon Inexperience as #1 Cause of this Lifelong Condition

Retrieved on: 
Wednesday, June 1, 2022

TAMPA, Fla., June 1, 2022 /PRNewswire/ --The Norman Parathyroid Center recognizes World Hypoparathyroidism Day, June 1, by highlighting its number one cause surgeon inexperience.

Key Points: 
  • TAMPA, Fla., June 1, 2022 /PRNewswire/ --The Norman Parathyroid Center recognizes World Hypoparathyroidism Day, June 1, by highlighting its number one cause surgeon inexperience.
  • Hypoparathyroidism is a very rare condition in the general population where it can occur in mild to moderate forms due to genetic problems.
  • On World Hypoparathyroidism Day, it is important to understand that more than 95% of patients with hypoparathyroidism have this problem as a complication from thyroid or parathyroid surgery.
  • World Hypoparathyroidism Day reminds us that the key to reducing the incidence of hypoparathyroidism lies in the hands of the patients.